Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
or

Biontech Se ADR (BNTX)

Biontech Se ADR (BNTX)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
102.02 -18.52 (-15.36%) 04/25/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 102.35 +0.33 (+0.32%) 19:58 ET
Quote Overview for Fri, Apr 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
93.17
Day High
118.73
Open 118.73
Previous Close 120.54 120.54
Volume 6,438,800 6,438,800
Avg Vol 1,512,065 1,512,065
Stochastic %K 79.53% 79.53%
Weighted Alpha -2.52 -2.52
5-Day Change +3.26 (+3.30%) +3.26 (+3.30%)
52-Week Range 76.53 - 131.49 76.53 - 131.49
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 21,129,448
  • Shares Outstanding, K 239,971
  • Annual Sales, $ 2,977 M
  • Annual Income, $ -719,920 K
  • EBIT $ -1,422 M
  • EBITDA $ -1,100 M
  • 60-Month Beta 1.07
  • Price/Sales 8.22
  • Price/Cash Flow N/A
  • Price/Book 1.16

Options Overview Details

View History
  • Implied Volatility 68.08% ( +14.98%)
  • Historical Volatility 73.85%
  • IV Percentile 99%
  • IV Rank 94.55%
  • IV High 70.47% on 04/08/25
  • IV Low 26.62% on 05/17/24
  • Put/Call Vol Ratio 0.69
  • Today's Volume 9,052
  • Volume Avg (30-Day) 1,780
  • Put/Call OI Ratio 0.75
  • Today's Open Interest 46,114
  • Open Int (30-Day) 45,297

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -2.77
  • Number of Estimates 8
  • High Estimate -1.33
  • Low Estimate -5.78
  • Prior Year -1.42
  • Growth Rate Est. (year over year) -95.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
81.20 +25.64%
on 04/07/25
Period Open: 97.05
120.62 -15.42%
on 04/24/25
+4.97 (+5.12%)
since 03/25/25
3-Month
81.20 +25.64%
on 04/07/25
Period Open: 118.14
126.77 -19.52%
on 01/29/25
-16.12 (-13.64%)
since 01/24/25
52-Week
76.53 +33.31%
on 08/05/24
Period Open: 86.71
131.49 -22.41%
on 09/17/24
+15.31 (+17.66%)
since 04/25/24

Most Recent Stories

More News
Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today

Shares of biotech companies involved in the development of monoclonal antibody cancer therapies were moving all over the place on Friday. Both U.S.-based Summit Therapeutics (NASDAQ: SMMT) and BioNTech...

SMMT : 23.47 (-36.06%)
AKESF : 13.5900 (+2.95%)
BNTX : 102.02 (-15.36%)
Novavax Retail Traders Rally In Defense After RFK Jr.'s COVID-19 Vaccine Skepticism Sends Stock Tumbling

Kennedy singled out the Novavax COVID-19 shot's single-antigen composition as the reason behind the delay in granting full approval.

NVAX : 6.67 (-5.66%)
MRNA : 27.22 (-0.62%)
PFE : 22.92 (+0.61%)
BNTX : 102.02 (-15.36%)
Pfizer Stock Falls to New 52-Week Low: Should You Buy the Dip?

Pfizer’s PFE stock hit a new 52-week low of $20.92 on Wednesday but recovered thereafter and closed at $22.49Though the stock has seen ups and downs in the past year, the latest price decline is largely...

LLY : 884.54 (+2.89%)
ABBV : 186.06 (+3.15%)
PFE : 22.92 (+0.61%)
BNTX : 102.02 (-15.36%)
Moderna Stock: Is MRNA Underperforming the Healthcare Sector?

As Moderna has underperformed its broader sector recently, analysts remain cautious about the stock’s prospects.

XLV : 138.05 (+0.48%)
NVAX : 6.67 (-5.66%)
MRNA : 27.22 (-0.62%)
PFE : 22.92 (+0.61%)
BNTX : 102.02 (-15.36%)
BioNTech's 2025 Revenue View, Vaccine Policy Uncertainty Prompt Price-Target Cut: Retail Stays Cautiously Optimistic

For the current year, BioNTech projected revenue of 1.7 billion euros to 2.2 billion euros, below the market consensus of 2.54 billion euros and a fall from last year's 2.75 billion euros.

IBB : 123.22 (-0.79%)
FNDF : 37.00 (+0.24%)
PFE : 22.92 (+0.61%)
BNTX : 102.02 (-15.36%)
BioNTech Se (BNTX) Q4 2024 Earnings Call Transcript

BNTX earnings call for the period ending December 31, 2024.

BNTX : 102.02 (-15.36%)
BioNTech Surpasses Q4 Revenue Estimates

BioNTech SE exceeded earnings expectations with strong oncology pipeline development, despite reduced vaccine revenue.

MRNA : 27.22 (-0.62%)
PFE : 22.92 (+0.61%)
BNTX : 102.02 (-15.36%)
Bank Rate Decision Due Next Week

U.S. Monday Featured Earnings Oracle Corporation (NYSE:ORCL) (Q3) EPS of $1.18, compared ...

BEKE : 21.40 (-3.08%)
XOMA : 24.14 (-0.37%)
ULTA : 383.67 (-0.59%)
EVEX : 3.65 (-4.95%)
MTN : 140.30 (+0.20%)
CCI : 100.19 (-0.56%)
ORCL : 138.49 (+0.71%)
DKS : 187.77 (-0.92%)
ENGH.TO : 24.85 (+0.04%)
BNTX : 102.02 (-15.36%)
GOGO : 7.62 (+2.83%)
FERG : 169.45 (-0.04%)
Here's Why Moderna Stock Soared 16% on Wednesday

Shares of Moderna MRNA rose nearly 16% yesterday after a couple of SEC filings showed that two board members bought shares on the open market. It also secured a legal victory in a patent dispute against...

MRNA : 27.22 (-0.62%)
PFE : 22.92 (+0.61%)
BNTX : 102.02 (-15.36%)
Pfizer's Q4 Earnings Beat Estimates, Non-Covid Drugs Drive Sales

Pfizer PFE reported fourth-quarter 2024 adjusted earnings per share of 63 cents, which beat the Zacks Consensus Estimate of 48 cents per share. The company had recorded earnings of 10 cents per share in...

ALNY : 251.56 (+3.69%)
PFE : 22.92 (+0.61%)
BMY : 47.90 (-1.62%)
BNTX : 102.02 (-15.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

BioNTech SE is a biotechnology company. It develops and commercializes immunotherapies for cancer and other diseases. BioNTech SE is based in Mainz, Germany.

See More

Key Turning Points

3rd Resistance Point 141.67
2nd Resistance Point 130.20
1st Resistance Point 116.11
Last Price 102.02
1st Support Level 90.55
2nd Support Level 79.08
3rd Support Level 64.99

See More

52-Week High 131.49
Fibonacci 61.8% 110.50
Fibonacci 50% 104.01
Last Price 102.02
Fibonacci 38.2% 97.52
52-Week Low 76.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective